Preoperative irradiation, lymphadenectomy, and 125iodine implantation for patients with localized carcinoma of the prostate.

Fifty-four patients with clinically and surgically localized prostatic carcinoma were treated with low-dose preoperative irradiation (1,050 cGy), pelvic lymphadenectomy, and interstitial 125Iodine implantation. The follow-up range is 2 to 9 years with a median follow-up of 5 years. Overall local tumor control is 92%. Actuarial 5-year survival is 86% and the actuarial disease-free survival at 5 years is 73%. Patients with poorly differentiated tumors have a significantly worse actuarial survival (62%) at 5 years than patients with well (95%) or moderately well differentiated tumors (93%), p = 0.04. Disease-free survival at 5 years was influenced by grade: well (100%), moderate (60%), and poor (48%), p = 0.03. Multivariate regression analysis indicates that only the degree of differentiation (p = 0.05) significantly impacts on survival. Both degree of differentiation (p = 0.04) and nodal status (p = 0.03) significantly influence disease-free survival. Potency has been maintained in 71% of patients potent at the time of implantation. Late reactions have been acceptable to date: bladder outlet obstruction (13%), mild proctitis (13%), cystourethritis (6%), incontinence (2%), and prostatic calculi (2%).

Prevalence of bothersome genitourinary symptoms and diagnoses in younger men on routine primary care visits.

OBJECTIVES: To assess the prevalence of bothersome genitourinary (GU) symptoms in younger men on routine primary care physician visits. METHODS: One hundred six men aged 18 to 50 years were approached to complete a brief, self-administered survey that included the American Urological Association Symptom Index, a benign prostatic hyperplasia (BPH) Impact Index, and additional questions about GU pain and sexual dysfunction and about a history of GU diseases. Men with GU symptoms had their outpatient records reviewed. RESULTS: Of the 101 respondents (mean age 36 years), 50% reported GU symptoms. Of these men, 25% were bothered by their symptoms and 17% wanted to talk about them with their physicians; 22% were worried that their GU symptoms might be due to prostate cancer; 27% of all men reported a history of at least one GU disease and 17% had more than one; 16% of all men had been to a urologist. Chart review for the 51 men with symptoms revealed physician documentation of GU symptoms in only 24% of cases and an abnormal GU examination in 8%. One third of reviewed charts documented a GU problem that visit. A broad spectrum of GU diagnoses was documented; no one cause predominated. Ninety percent of all men reported that primary care physicians should routinely ask younger men GU questions as part of their general healthcare. CONCLUSIONS: The high prevalence of bothersome GU symptoms and diagnoses in younger men suggests that information about the clinical, functional, and quality of life implications of these symptoms needs to be collected in this population.

Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma.

OBJECTIVES: To analyze the experience and the results of partial nephrectomy in a single institution over the last 10 years in order to optimize patient selection and minimize morbidity. METHODS: This is a retrospective chart review of 64 patients (mean age 56.6 years, range 18 to 88; 43 men, 21 women) who underwent 66 partial nephrectomies at the Brigham and Women's Hospital between 1987 and 1997. Preoperatively, 62% of the patients had no symptoms, whereas 38% had pain and/or hematuria. The indications were elective in 23 patients, solitary kidney in 28 (14 with bilateral asynchronous tumor), bilateral synchronous tumor in 7, von Hippel-Lindau disease with normal contralateral kidney in 3, lymphoma in 3, and other indications in 2 patients. Surgery was performed for solid or indeterminate renal mass suspected of being renal cell carcinoma in 58 patients. RESULTS: The most common final pathologic diagnosis was renal cell carcinoma in 47 procedures. One or more complications occurred after 18 procedures (15 with solitary kidney and 3 in patients with normal contralateral kidney) or 27% of the patients. The most common complication was an increased creatinine level (two times the baseline), occurring in 10 procedures (15.1%). Transfusion was necessary in 37 of 66 procedures (56%), and the mean blood loss was 836 cc (range 100 to 3200). Regarding renal function, 85% of the patients had a minimal increase in creatinine of less than 0.5 mg/dL after surgery (all patients with a normal contralateral kidney are in this group); 3 patients required either temporary (n = 1) or permanent (n = 2) dialysis. Other complications are also described. The mean length of stay among 65 patients was 6.5 days (range 3 to 14). The differences between length of stay, blood loss, and tumor size were statistically significant between the solitary kidney group and the elective indications group (P < 0.001). CONCLUSIONS: Nephron sparing surgery is feasible and relatively safe in patients with a normal contralateral kidney. Awareness of potential complications should aid in the selection of appropriate patients for this procedure.

Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits.

OBJECTIVES: The morbidity of chronic prostatitis results from a constellation of genitourinary symptoms. A recent study classified 21 of these symptoms into three categories: pain, voiding complaints, and sexual dysfunction. Pain symptoms predominated among patients with prostatitis. Using data from a nationwide survey of physician visits, we examined the most common symptoms reported by men at chronic prostatitis visits and contrasted the results with visits for benign prostatic hyperplasia (BPH). METHODS: We analyzed 81,034 visits by men (18 years and older) to office-based physicians of all specialties in the National Ambulatory Medical Care Surveys of 1990 to 1996, using sampling weights to make national estimates. U.S. physicians selected by random stratified sampling completed visit forms that included patients' reasons for visits and physicians' diagnoses. RESULTS: In 1990 to 1996, there were 765 visits (national estimate 1.5 million visits/yr; 95% confidence interval = 0.9 to 2.1) with a diagnosis of chronic prostatitis. Among chronic prostatitis visits, 20% were for pain, 19% for urinary symptoms, and 1% for sexual dysfunction. Among 2271 BPH visits, 2% were for pain, 33% for voiding complaints, and 1% for sexual dysfunction. The most common reason coded for chronic prostatitis visits was painful urination (14% of chronic prostatitis visits, but only 1.7% of BPH visits). CONCLUSIONS: Pain was slightly more common than voiding complaints, but much more common than sexual dysfunction among chronic prostatitis visits. The most common reason for chronic prostatitis visits was painful urination, which was uncommon among patients with BPH. Pain distinguished chronic prostatitis from BPH better than any other urinary symptom.

The interstitial cystitis symptom index and problem index.

OBJECTIVES: To develop 2 brief self-administered indices for measuring lower urinary tract symptoms and their impact in patients with interstitial cystitis (IC). METHODS: An initial set of questions was developed and evaluated in focus groups. The index was revised, shortened, and validated with patients diagnosed in 3 large urologic practices with experience in interstitial cystitis (N = 45). Controls were recruited from a group of healthy volunteers in a gynecology clinic (N = 67). Internal consistency, construct validity, and test-retest reliability were evaluated. RESULTS: The IC symptom index and the IC problem index measure urinary and pain symptoms and assesses how problematic symptoms are for patients with interstitial cystitis. Psychometric performance of both instruments is good, with the symptom index demonstrating excellent ability to discriminate characteristics between patients and controls. CONCLUSION: Both indices should be useful in the evaluation and management of patients with IC and should be particularly useful in clinical trials of new therapies for this condition, where reliable, validated, and reproducible outcome measures are critically important.

A brief male sexual function inventory for urology.

OBJECTIVES: To develop a brief questionnaire to measure male sexual function. METHODS: An initial set of questions was refined and reduced through cognitive testing and two serial validation studies. In each study, men were recruited from a sexual dysfunction clinic and a general medicine practice to complete the instrument. Test-retest reliabilities, internal consistencies, and construct validities were examined. RESULTS: The final instrument covers sexual drive (two items), erection (three items), ejaculation (two items), perceptions of problems in each area (three items), and overall satisfaction (one item). Psychometric performance was generally very satisfactory, although self-assessments of ejaculate volume are problematic. Translations have been developed and pilot tested in a number of languages. CONCLUSIONS: The Brief Sexual Function Inventory may be useful for measuring male sexual function in practice and research.

Distribution of the Brief Male Sexual Inventory in community men.

The objectives of the study were to characterize male sexual functioning as related to age in community-dwelling older men. In 1989, a random sample of men aged 40-79 y (n=2115) without prior prostate surgery, prostate cancer, or other conditions known to affect voiding function (except benign prostatic hyperplasia) was invited (55% agreed) to participate in the Olmsted County Study of Urinary Symptoms and Health Status Among Men. In 1996, a previously validated male sexual function questionnaire was administered to the cohort. The questionnaire has 11 questions measuring sexual drive (two questions); erectile function (three) and ejaculatory function (two), as well as assessing problems with sex drive, erections, or ejaculation (three); and overall satisfaction with sex life (one). Each question is scored on a scale of 0-4, with higher scores indicating better functioning. Cross-sectional age-specific means (+/-s.d.) for drive, erections, ejaculation, problems, and overall satisfaction declined from 5.2 (+/-1.5), 9.8 (+/-2.5), 7.4 (+/-1.4), 10.7 (+/-2.2), and 2.6 (+/-1.0), respectively, for men in their 40s to 2.4 (+/-1.6), 3.3 (+/-3.4), 3.6 (+/-3.2), 7.7 (+/-3.8), and 2.1 (+/-1.2) for men 70 y and older (all P<0.001). The cross-sectional decline in function with age was not constant, with age-related patterns differing by domain. The percentage of men reporting erections firm enough to have intercourse in the past 30 days declined from 97% (454/468) among those in their 40s to 51% (180/354) among those in their 80s (P&<0.001). In age-adjusted analyses, men reporting regular sexual partners had statistically significantly higher levels of sex drive, erectile function, ejaculatory function, and overall satisfaction than those who did not report regular sexual partners. Sexual drive, erectile functioning, ejaculatory functioning, and overall sexual satisfaction in men show somewhat differing cross-sectional patterns of decline with advancing age. Active sexual functioning is maintained well into the 80s in a substantial minority of community-dwelling men.

Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores.

Urinary symptom severity can be documented objectively among men with BPH using validated instruments such as the AUA Symptom Index. The AUA Index was developed to discriminate among BPH patients who are more or less bothered by their condition, and to measure change in symptom levels over time or with treatment. The AUA Index is reliable and valid for these purposes and can be useful in both clinical practice and research. The role of symptom measurement in general and the AUA Index in particular in the diagnosis of BPH is unclear and may be limited. Additional research is needed to maximize the utility of symptom measurement in urology.

Minilaparotomy for laparoscopy: not a foolproof procedure.

Minilaparotomy with placement of a trocar under direct vision has been felt to be a safe approach for establishing access to the intra-abdominal contents during laparoscopy. However, there is potential for hollow viscus injury. We report a case of a 23-year-old man whose small bowel was injured during placement of a Hasson trocar at the time of laparoscopic varix ligation. The literature on laparoscopic complications is reviewed, and recommendations for avoiding difficulties are outlined.

Dutasteride significantly improves quality of life measures in patients with enlarged prostate.

The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

Fractured penis: a review.

Fracture of the penis is a well-recognized clinical entity. The ideal management has evolved and repair remains largely surgical. We present the etiology and pathophysiology of this condition and outline the therapeutic options.

Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).

OBJECTIVES: The NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) was developed to assess symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). We assessed the responsiveness of the NIH-CPSI to change over time and defined thresholds for changes perceptible to patients. METHODS: We studied 174 men with CP/CPPS who participated in a placebo-controlled randomized clinical trial. Changes from baseline to six weeks in the NIH-CPSI total score and pain, urinary, and quality of life subscores were compared to a global response assessment (GRA). Effect sizes and Guyatt statistics were calculated to evaluate responsiveness; 95% confidence intervals were produced using bootstrapping. RESULTS: All scores decreased over time with the largest decrease in subjects who reported on the GRA that they were markedly improved. The NIH-CPSI total, pain, and quality of life scores were highly responsive in the improved groups; the urinary score showed minimal responsiveness. There was no evidence of responsiveness among those subjects who worsened on the trial. ROC curves identified a 6-point decline in the NIH-CPSI total score as the optimal threshold to predict treatment response. CONCLUSIONS: The NIH-CPSI total score and pain and quality of life subscores are responsive to change over time.

Tamsulosin: current clinical experience.

During the past decade, our understanding of the epidemiology and natural history of benign prostatic hyperplasia (BPH) has improved considerably. Population-based studies confirm that lower urinary tract symptoms (LUTS) are very common among aging men. These studies have confirmed that men with moderate-to-severe symptoms have 4 to 6 times more trouble and interference with activities of daily living and twice the level of worry as those with mild symptoms. The realization by patients and their physicians that most men >50 years of age will develop LUTS, has resulted in increased awareness of pharmacologic agents, principally alpha-adrenergic antagonists, as a first line of therapy for this condition. Alpha blockers were introduced >30 years ago to treat LUTS and today are the mainstay in pharmacologic therapy. Among the alpha blockers, tamsulosin more selectively targets the alpha(1A)-adrenergic receptor subtype and is as effective as conventional alpha(1) blockers in treating LUTS caused by BPH. Its subselectivity and pharmacodynamic properties may provide advantages in safety, tolerability, and administration compared with other alpha blockers, such as terazosin and doxazosin. Unlike other alpha blockers, tamsulosin does not require titration to be efficacious. Because of its rapid onset of action and lack of clinically significant effect on blood pressure in normotensive and hypertensive patients, a therapeutic dose is delivered at the onset of treatment. Studies have documented that tamsulosin produces rapid improvements in LUTS and peak urinary flow rates, and these responses have been found to be durable.

Quality of life and sexuality: methodological aspects.

Benign prostatic hyperplasia (BPH) can impact significantly on a patient's quality of life (QOL), including sexual functioning. With increased life expectancy, this aspect of the disease is becoming increasingly important. Symptom severity can be measured using a number of instruments, the most common one being the International Prostate Symptom Score (IPSS). A number of studies have shown that symptom severity is correlated with decreased QOL, i.e. the more severe the symptoms, the greater the impact on QOL. Specific questionnaires have been developed to address the issue of sexual function, including the Brief Sexual Function Inventory and the International Index of Erectile Function. Importantly, these instruments can usefully be applied to assess the effect of the various therapies for BPH on sexual function. In general, the alpha(1)-blockers have minimal impact on sexual function, compared with finasteride, which can affect libido, ejaculation and erectile function itself.

LUTS, ED, QOL: alphabet soup or real concerns to aging men?

The severity of symptoms and the degree to which they negatively impact on quality of life (QOL) are the major factors prompting patients with benign prostatic hyperplasia (BPH) to seek treatment. Several tools have been developed to assess symptom severity in patients with BPH, including the International Prostate Symptom Score (IPSS), the Danish Prostate Symptom Score (DAN-PSS), and the International Continence Society (ICS) questionnaire. Data from the Veterans Affairs Cooperative Study show that reductions in IPSS scores predict global ratings of improvement with treatment. Instruments have also been developed to measure the impact of urinary symptoms on QOL and have shown that as symptom severity increases, the impact on QOL also increases. Data from studies conducted in the United States, France, Scotland, and Japan reveal a similar pattern regarding the impact of symptom severity on QOL. Studies have also demonstrated that medical treatment with alpha-blockers, for example, is associated with a reduction in symptoms and a corresponding improvement in QOL. Patients with BPH frequently also have coexisting erectile dysfunction, which significantly affects QOL. Thus, in addition to assessment of symptoms and QOL in patients with BPH, sexual function should also be assessed in these patients.

alpha(1)-Blockade in the nineties: focus on the patient.

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are prevalent in 14-19% of men in their 40s, increasing to 43% in men >60 y. Symptoms impact on patient's quality of life to varying degrees and more recently have been shown to affect sexual function. A number of question-naires are available which can assess symptom severity, quality of life and sexual function. Comparative studies in different countries show a similar trend, in that as symptom severity increases, then so does the interference with quality of life, general health status and sexual function. Treatment of LUTS is associated with an improvement in the quality of life of the patient. alpha(1)-Blockers are an established treatment of LUTS associated with BPH and, in addition, the alpha(1)-blocker alfuzosin has been shown to improve sexual drive and function. It is not yet known, however, whether this is a direct effect or due to a general improvement in the patient's quality of life. When treating BPH, physicians should be aware of the quality of life aspects to the disease, including sexual function, which is still an important feature in the ageing male.